Dermasol™
Clobetasol Propionate BP

COMPOSITION
Dermasol™ 0.05% cream: Each gm cream contains Clobetasol Propionate BP 0.5 mg.
Dermasol™ 0.05% ointment: Each gm ointment contains Clobetasol Propionate BP 0.5 mg.
Dermasol™-S: Each gm Scalp Solution contains Clobetasol propionate BP 0.5 mg.

PHARMACOLOGY
Clobetasol Propionate is a highly potent topical steroid. It has both local anti-inflammatory and immunosuppressive activity. Clobetasol, as the Propionate salt, is only used topically on the skin and its effects are limited to the local anti-inflammatory activity. When given systemically it has standard glucocorticoid activity and binds with high affinity to the glucocorticoid receptor. Clobetasol Propionate inhibits the adherence of neutrophils and monocyte-macrophages; to the capillary endothelial cells of inflammed area. Clobetasol blocks the effect of macrophage migration inhibitory factor and decreases the activation of plasminogen to plasmin.

INDICATION
Dermasol™ is indicated in:
1. Initial control of all forms of hyperacute eczema in all age groups (in children for no longer than a few days)
2. Chronic hyperkeratotic eczema of the hands and feet and patches of chronic lichen simplex
3. Chronic hyperkeratotic psoriasis of any area of the body
4. Severe acute photosensitivity
5. Hypertrophic lichen planus
6. Localized bullous disorders
7. Keloid scarring
8. Pretibial myxoedema
9. Vitiligo
10. Suppression of reaction after cryotherapy

Dermasol™-S Scalp Solution is indicated in the topical therapy of recalcitrant corticosteroid-responsive dermatoses of the scalp, including recalcitrant cases of psoriasis and seborrheic dermatitis.
DOSAGE AND ADMINISTRATION

Dermasol™ Cream and Ointment:
Apply sparingly to the affected area once or twice daily until improvement occurs. As with other highly active topical steroid preparations, therapy should be discontinued when control is achieved. If a longer course is necessary, it is recommended that treatment should not be continued for more than four weeks without the patient's condition being observed. Repeated short courses of Dermasol™ may be used to control exacerbations. If continuous steroid treatment is necessary, a less potent preparation should be used. In very resistant lesions, especially where there is hyperkeratosis, the anti-inflammatory effect of Dermasol™ can be enhanced, if necessary, by occluding the treatment area with polythene film. Only overnight occlusion is usually adequate to bring about a satisfactory response. Thereafter, improvement can usually be maintained by application without occlusion.

Dermasol™-S:
Should be applied once or twice daily to the affected areas of the scalp and rubbed in gently.

CONTRAINDICATION AND PRECAUTION
Clobetasol Propionate is contraindicated in:
1. Cutaneous infections such as impetigo, tinea corporis and herpes simplex
2. Infestations such as scabies
3. Neonates (Children less than one year old)
4. Acne vulgaris
5. Rosacea
6. Gravitational ulceration
Long term continuous therapy with Clobetasol Propionate should be avoided, particularly in infants and children, in whom adrenal suppression occurs readily. If Clobetasol Propionate is required for use in children, it is recommended that the treatment should be reviewed on weekly basis. It should be noted that the infant’s napkin may act as occlusive dressing. The face more than other area of the body, may exhibit atrophic changes after prolonged treatment with potent topical corticosteroids. This must be borne in mind when treating facial conditions which warrants use of Clobetasol Propionate and frequent observation of the patient is important.

SIDE EFFECT
Provided the weekly dosage is less than 50 g in adults, any pituitary-adrenal suppression is likely to be transient with a rapid return to normal values once the short course of
steroid therapy has ceased. The same applies to children given proportionate dosage. Use of occlusive dressings increases the absorption of topical corticosteroids. Prolonged and intensive treatment with a highly active corticosteroid preparation may cause atrophic changes, such as thinning, striae and dilatation of the superficial blood vessels, particularly when occlusive dressings are used or where skin folds are involved.

USE IN PREGNANCY AND LACTATION
Clobetasol Propionate should be avoided in pregnant women. Mothers using large amounts of the drug should be aware of potential excretion in milk.

USE IN CHILDREN
The safety and effectiveness of the preparation has not been established in children below the age of 12 years.

OVERDOSE
Acute overdose is very unlikely to occur. However, in the case of chronic over dosage or misuse, the features of hypercorticism may appear and in this situation topical steroids should be discontinued.

STORAGE
Store in a cool and dry place, away from light. Keep out of reach of children.

HOW SUPPLIED
Dermasol™ 10 gm cream: Each pack has a laminated tube containing 10 gm of the cream.
Dermasol™ 10 gm ointment: Each pack has a laminated tube containing 10 gm of the ointment.
Dermasol™ 20 gm cream: Each pack has a laminated tube containing 20 gm of the cream.
Dermasol™ 20 gm ointment: Each pack has a laminated tube containing 20 gm of the ointment.
Dermasol™-S: Each container contains 30 ml Scalp Solution.